Release date: 2 October 2020
Promoter – Financial Intermediary
COUNTERPART(S) TO BE DETERMINED
The operation aims at increasing the local manufacturing capacity of active pharmaceutical ingredients (APIs) in sub-Saharan Africa (SSA).
The operation aims at increasing the local manufacturing capacity of active pharmaceutical ingredients (APIs) in sub-Saharan Africa. The ultimate objective is to improve the availability of pharmaceutical products in the region and to increase the robustness of the pharmaceutical supply chain by reducing dependency on imports.
- Health - Human health and social work activities
Proposed EIB finance (Approximate amount)
EUR 50 million
Total cost (Approximate amount)
EUR 100 million
The overall environmental impact and the residual environmental risks of the operation are unknown at this stage and will be assessed at the appraisal of individual sub-operations. The Bank will require the beneficiaries to ensure that implementation of the sub-projects will be done in accordance with the Bank's environmental and social policy and standards.
The Bank will require that the beneficiaries ensure that the implementation of the sub-operations will be done in accordance with the Bank's Guide to Procurement.
Approved - 11/11/2020
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).